Combination sclerotherapy and band ligation for refractory transfusion-dependent nodular gastric antral vascular ectasia (GAVE): inducing submucosal scarring.

Patrick T Magahis, Thomas J Wang, Daniel J Stein, Kathleen Viveiros, Steven D Zucker, Marvin Ryou

Abstract readCase Reports

In one paragraph

Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Patrick T MagahisDepartment of Medicine, Harvard Medical School, Brigham and Women's Hospital, 45 Francis St., ASB-2, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0002-2083-3398

Thomas J WangDivision of Gastroenterology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.

Daniel J SteinDepartment of Medicine, Harvard Medical School, Brigham and Women's Hospital, 45 Francis St., ASB-2, Boston, MA, 02115, USA.

Kathleen ViveirosDepartment of Medicine, Harvard Medical School, Brigham and Women's Hospital, 45 Francis St., ASB-2, Boston, MA, 02115, USA.

Steven D ZuckerDepartment of Medicine, Harvard Medical School, Brigham and Women's Hospital, 45 Francis St., ASB-2, Boston, MA, 02115, USA.

Marvin RyouDepartment of Medicine, Harvard Medical School, Brigham and Women's Hospital, 45 Francis St., ASB-2, Boston, MA, 02115, USA. mryou@bwh.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNodular GAVE is a rare variant more common in cirrhosis that often does not respond to conventional endoscopic therapies. We present a case series of patients with cirrhosis and transfusion-dependent refractory nodular GAVE managed with serial combination sclerotherapy with sodium tetradecyl sulfate (STS) and band ligation.

methodsWe report baseline characteristics and transfusion-related outcomes for 4 consecutive patients who underwent combination therapy.

resultsSTS was administered every 1 to 2 months, with the total number of sessions ranging from 5 to 8 over a median 12.3 months. One moderate adverse event, a large gastric ulcer that ultimately fully healed, occurred. At a median follow-up of 40.4 months, the frequency of transfusions had declined from 1.0 to 2.5 per month to 0 to 0.2 per month. The mean hemoglobin levels increased from 7.7 to 10.9 g/dL.

conclusionsCombination sclerotherapy and band ligation resulted in a durable reduction in transfusion requirements and substantially increased hemoglobin for patients with cirrhosis and refractory nodular GAVE. It is postulated that STS injection may limit neovascularization driving nodular GAVE recurrence.

Indexed as

Gastric Antral Vascular EctasiaSclerotherapyAgedBlood TransfusionCombined Modality TherapyFemaleHumansLigationLiver CirrhosisMaleMiddle AgedSclerosing SolutionsSodium Tetradecyl SulfateTreatment OutcomeSclerosing SolutionsSodium Tetradecyl SulfateAblation therapyCirrhosisLiver diseaseSclerosant injection

Identifiers

PMID42250180

DOI10.1007/s12328-026-02374-5

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.